Bunolol: A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
ID Source | ID |
---|---|
PubMed CID | 3914 |
CHEMBL ID | 293030 |
CHEBI ID | 29110 |
SCHEMBL ID | 828612 |
MeSH ID | M0003035 |
Synonym |
---|
27591-01-1 |
(+/-)-5-[(tert-butylaminol)-2'-hydroxypropoxy]-3,4-dihydro-1(2h)-naphthalenone |
CHEBI:29110 , |
(+-)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2h)-one |
bunolol |
5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2h)-one |
brn 1887243 |
bunolol [inn] |
3,4-dihydro-5-(3-(tert-butylamino)-2-hydroxy)propoxy-1(2h)-naphthalenone |
bunololo [dcit] |
1(2h)-naphthalenone, 3,4-dihydro-5-(3-(tert-butylamino)-2-hydroxypropoxy)- |
bunololum [inn-latin] |
(+/-)-5-[(tert-butylamino)-2'-hydroxypropoxy]-3,4-dihydro-1(2h)-naphthalenone |
C04883 , |
(+/-)-bunolol |
CHEMBL293030 |
L000824 |
5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2h-naphthalen-1-one |
71qsy2ut3g , |
bunololo |
bunololum |
unii-71qsy2ut3g |
FT-0604397 |
(+/-)-5-(3-(tert-butylamino)-2-hydroxypropoxy)-3,4-dihydro-1(2h)-naphthalenone |
bunolol [mart.] |
1(2h)-naphthalenone, 5-(3-(1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, (+/-)- |
SCHEMBL828612 |
5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1(2h)-naphthalenone # |
(-)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1(2h)- naphthalenone |
IXHBTMCLRNMKHZ-UHFFFAOYSA-N |
AB01563321_01 |
DTXSID7022702 |
1(2h)-naphthalenone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro- |
SBI-0206800.P001 |
NCGC00263903-02 |
(?)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalene-1(2h)-one hydrochloride,(?)-bunolol hydrochloride |
Q27104064 |
BRD-A46876182-003-01-0 |
racemic bunolol;dl-bunolol |
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Class | Description |
---|---|
naphthalenone | Any naphthalene that is carrying at least one oxo substituent. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
cytochrome P450 2D6 | Homo sapiens (human) | Potency | 37.9083 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Alpha-2A adrenergic receptor | Homo sapiens (human) | Kapp | 0.0170 | 0.0170 | 0.0370 | 0.0930 | AID1123537 |
Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | Kapp | 0.0170 | 0.0170 | 0.0370 | 0.0930 | AID1123537 |
Alpha-2B adrenergic receptor | Homo sapiens (human) | Kapp | 0.0170 | 0.0170 | 0.0370 | 0.0930 | AID1123537 |
Beta-1 adrenergic receptor | Rattus norvegicus (Norway rat) | Kapp | 0.0150 | 0.0077 | 0.0119 | 0.0150 | AID1123536 |
Alpha-2C adrenergic receptor | Homo sapiens (human) | Kapp | 0.0170 | 0.0170 | 0.0370 | 0.0930 | AID1123537 |
Alpha-1D adrenergic receptor | Homo sapiens (human) | Kapp | 0.0170 | 0.0170 | 0.0370 | 0.0930 | AID1123537 |
Alpha-1A adrenergic receptor | Homo sapiens (human) | Kapp | 0.0170 | 0.0170 | 0.0370 | 0.0930 | AID1123537 |
Alpha-1B adrenergic receptor | Homo sapiens (human) | Kapp | 0.0170 | 0.0170 | 0.0370 | 0.0930 | AID1123537 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1136407 | Myocardial depressant activity in guinea pig atrial muscle assessed as maximal non-depressant dose by measuring contractility | 1978 | Journal of medicinal chemistry, Sep, Volume: 21, Issue:9 | Nondepressant beta-adrenergic blocking agents. 1. Substituted 3-amino-1-(5,6,7,8-tetrahydro-1-naphthoxy)-2-propanols. |
AID1123536 | Displacement of [3H]DHA from beta1 adrenergic receptor in rat ventricular muscle by competitive binding assay | 1979 | Journal of medicinal chemistry, Jun, Volume: 22, Issue:6 | Cardioselectivity of beta-adrenoceptor blocking agents 1. 1-[(4-Hydroxyphenethyl)amino]-3-(aryloxy)propan-2-ols. |
AID1136404 | Inhibition of beta-adrenergic receptor in isoproterenol-stimulated guinea pig atrial muscle | 1978 | Journal of medicinal chemistry, Sep, Volume: 21, Issue:9 | Nondepressant beta-adrenergic blocking agents. 1. Substituted 3-amino-1-(5,6,7,8-tetrahydro-1-naphthoxy)-2-propanols. |
AID1123538 | Cardio selectivity ratio of Kapp for beta2 adrenergic receptor in rat lung muscle to Kapp for beta1 adrenergic receptor in rat ventricular muscle | 1979 | Journal of medicinal chemistry, Jun, Volume: 22, Issue:6 | Cardioselectivity of beta-adrenoceptor blocking agents 1. 1-[(4-Hydroxyphenethyl)amino]-3-(aryloxy)propan-2-ols. |
AID1123537 | Displacement of [3H]DHA from beta2 adrenergic receptor in rat lung muscle by competitive binding assay | 1979 | Journal of medicinal chemistry, Jun, Volume: 22, Issue:6 | Cardioselectivity of beta-adrenoceptor blocking agents 1. 1-[(4-Hydroxyphenethyl)amino]-3-(aryloxy)propan-2-ols. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.86) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |